Is N-Acetyl Semax Amidate stronger than Semax?

No published study compares them. The modification is intended to slow enzymatic breakdown, which would affect duration rather than strength, and even that has not been demonstrated for this molecule in the indexed literature.

What does the acetyl and amide modification do?

Exopeptidases attack peptides from their ends, so capping both ends is a standard way to slow clearance. It is aimed at duration, not at changing the mechanism.

Does the Semax research apply to this compound?

Only by assumption. The molecules differ at both termini, and terminal charge affects receptor interaction and distribution. Whether the change is pharmacologically silent has not been tested.

Has N-Acetyl Semax Amidate been studied in humans?

No published study of this modified molecule in humans was found. Semax has clinical use in Russia; that is the parent peptide, not this one.

Is it an approved medicine?

No, in any jurisdiction. It is supplied here as a laboratory reagent for in-vitro research and not for human or veterinary use.

Research guides

N-Acetyl Semax Amidate: what the research says

A terminally capped Semax with no literature of its own. What the capping is meant to do, and why every claim about it is borrowed from a different molecule.

Available in the catalogue

Supplied as research material. Sizes and pricing are on the product page. Availability is not a statement about what a compound does.

NA SEMAX AMIDATE
Nootropic & Cognitive

The most important thing to know about this compound is that the studies people cite for it were not conducted on it. That is not a criticism of the molecule; it is a statement about what evidence exists, and it is the reason this article is separate from the Semax one.

What the molecule is

Semax with an acetyl group added at the N-terminus and an amide at the C-terminus — the same seven-residue core, capped at both ends.

What capping is for

Terminal capping is a standard and well-understood medicinal chemistry technique. Exopeptidases attack peptides from their ends, so blocking both ends slows enzymatic clearance. The modification is aimed at duration, not at changing what the molecule does, and on that reasoning the underlying pharmacology is expected to be Semax's.

The reasoning is sound and it is still reasoning. Capping a peptide changes its charge distribution at both termini, and charge affects receptor interaction, transport and distribution. Whether the modification is pharmacologically silent is an empirical question, and for this molecule it has not been answered in published work.

What that means for reading claims about it

Every efficacy claim in circulation for this compound traces back to the Semax literature — the BDNF work in rat basal forebrain, the Russian clinical use — via the assumption that the capped molecule behaves identically. Even if that assumption is correct, the resulting claim is weaker than the same claim about Semax, because it carries an additional untested step.

The honest position is that this is Semax with a plausible durability modification and no independent evidence base. Anyone comparing the two should be comparing a peptide with a literature against a peptide with an inference.

What studies reported

Each entry states what a study examined and the model it used. Nothing below describes an outcome for a person.

Everything below is drawn from published research, and each entry names the model the study used. Approval status varies by compound and by country, and nothing described here is supplied as a medicine or for use in a person.

Adverse and null findings reported

No dedicated safety study has been published for this compound. That is not a finding that none exists — it means the question has not been asked in print, and the gaps below say so.

What the research does not establish

An absence cannot be cited, so these are stated plainly. They are the part of the picture that silence would otherwise hide.

Both citation lists are empty because no published study was found that investigated this modified molecule specifically. Everything cited for it in practice is Semax literature.
Whether N-terminal acetylation and C-terminal amidation leave the pharmacology of Semax unchanged has not been tested and published. It is a reasonable expectation, not a finding.
No pharmacokinetic study establishing that the capped form actually persists longer than Semax appears in the indexed literature. The durability rationale is the reason the molecule exists and it is itself uncited.
It holds no marketing authorisation anywhere. Unlike Semax, it is not a registered medicine in Russia either — the registration covers the parent peptide.
Analytical work on seized research-peptide preparations has found material that did not match its label. For a molecule distinguished from its parent only by two terminal modifications, identity is a question a certificate of analysis has to answer rather than assume.
No safety data of any kind specific to this molecule has been published.

Common questions

Is N-Acetyl Semax Amidate stronger than Semax?: No published study compares them. The modification is intended to slow enzymatic breakdown, which would affect duration rather than strength, and even that has not been demonstrated for this molecule in the indexed literature.
What does the acetyl and amide modification do?: Exopeptidases attack peptides from their ends, so capping both ends is a standard way to slow clearance. It is aimed at duration, not at changing the mechanism.
Does the Semax research apply to this compound?: Only by assumption. The molecules differ at both termini, and terminal charge affects receptor interaction and distribution. Whether the change is pharmacologically silent has not been tested.
Has N-Acetyl Semax Amidate been studied in humans?: No published study of this modified molecule in humans was found. Semax has clinical use in Russia; that is the parent peptide, not this one.
Is it an approved medicine?: No, in any jurisdiction. It is supplied here as a laboratory reagent for in-vitro research and not for human or veterinary use.

Compounds covered

The reference page for each compound this article discusses.

N-Acetyl Semax Amidate

Semax: what the research says
An ACTH(4-10) analogue registered as a medicine in Russia and unknown to Western regulators. What the BDNF work reported, and why the English record looks thin.
N-Acetyl Selank Amidate: what the research says
Selank with both termini capped, and the same evidence problem as its Semax counterpart: a plausible stability modification nobody has published a study on.
Peptide shelf life and stability
How long lyophilised and reconstituted peptides keep, and the four things that shorten it: temperature, moisture, light and oxidation. Storage figures included.

About this article

Everything reported here comes from published research, and each finding names the model the study used — cell culture, rat, or human. Findings in one model do not transfer to another, most of the work described is preclinical, and none of it is a claim that a compound is safe or effective for any purpose. Nothing on this page describes doses, routes of administration, or use in a person.

Approval status varies by compound and by country. A few of the substances described are the active ingredient of medicines authorised in the EU; most have no marketing authorisation anywhere and have never been assessed by a regulator. Neither is supplied as a medicine here. All material supplied by ASSAY is sold for in-vitro laboratory research only, and is not a drug, food, cosmetic or medical device, and not for human or veterinary use.

All guides